一种快速、低成本的血液检测方法，能可靠地检测多种不同类型的癌症将具有变革性。在这个大规模的发现性研究中（n=2092例患者），我们使用了Dxcover® Cancer Liquid Biopsy来检测八种不同类型的癌症。该检测方法使用傅里叶变换红外（FTIR）光谱学和机器学习算法来检测癌症。针对八种癌症类型和有症状非癌症对照组，计算了受试敏感性值曲线（ROC），其中包括脑癌（0.90）、乳腺癌（0.76）、结肠癌（0.91）、肾癌（0.91）、肺癌（0.91）、卵巢癌（0.86）、胰腺癌（0.84）和前列腺癌（0.86）。我们评估了当所有八种癌症类型一起对非癌症患者进行分类时的检测性能。当特异性为99%时，癌症与无症状非癌症的分类可以检测到64%的一期癌症（总体敏感性57%）。当调整为更高的敏感性时，该模型可以检测到99%的一期癌症（特异性59%）。这种光谱血液检测方法可以有效检测早期疾病，并可以根据不同医疗保健系统和癌症诊断路径的需求进行灵活调整，以实现最大的敏感性或特异性。这种低成本策略有助于提前诊断癌症，从而使癌症治疗更加有效或更少有毒。提前诊断癌症对于提高患者的生存率至关重要。目前的液体活检主要集中在单一肿瘤标志物上，这限制了检测的敏感性，尤其是对于不释放足够基因材料的早期癌症。这种全组学液体活检分析了血液衍生物中存在的肿瘤和免疫衍生标志物的全部组分，有助于早期检测多种癌症。将这种血液检测方法整合到现有的诊断路径中的门槛较低，因为该技术快速、易于使用，只需要微量样本量，样本准备量也很小。此外，本研究中描述的光谱液体活检方法有可能与其他正交测试方法结合，如游离DNA，从而提供一条高效的诊断途径。早期给予癌症治疗可能更加有效，这种低成本策略有潜力改善患者的预后。© 2023年。作者。

A rapid, low-cost blood test that can be applied to reliably detect multiple different cancer types would be transformational.In this large-scale discovery study (n = 2092 patients) we applied the Dxcover® Cancer Liquid Biopsy to examine eight different cancers. The test uses Fourier transform infrared (FTIR) spectroscopy and machine-learning algorithms to detect cancer.Area under the receiver operating characteristic curve (ROC) values were calculated for eight cancer types versus symptomatic non-cancer controls: brain (0.90), breast (0.76), colorectal (0.91), kidney (0.91), lung (0.91), ovarian (0.86), pancreatic (0.84) and prostate (0.86). We assessed the test performance when all eight cancer types were pooled to classify 'any cancer' against non-cancer patients. The cancer versus asymptomatic non-cancer classification detected 64% of Stage I cancers when specificity was 99% (overall sensitivity 57%). When tuned for higher sensitivity, this model identified 99% of Stage I cancers (with specificity 59%).This spectroscopic blood test can effectively detect early-stage disease and can be fine-tuned to maximise either sensitivity or specificity depending on the requirements from different healthcare systems and cancer diagnostic pathways. This low-cost strategy could facilitate the requisite earlier diagnosis, when cancer treatment can be more effective, or less toxic.The earlier diagnosis of cancer is of paramount importance to improve patient survival. Current liquid biopsies are mainly focused on single tumour-derived biomarkers, which limits test sensitivity, especially for early-stage cancers that do not shed enough genetic material. This pan-omic liquid biopsy analyses the full complement of tumour and immune-derived markers present within blood derivatives and could facilitate the earlier detection of multiple cancer types. There is a low barrier to integrating this blood test into existing diagnostic pathways since the technology is rapid, simple to use, only minute sample volumes are required, and sample preparation is minimal. In addition, the spectroscopic liquid biopsy described in this study has the potential to be combined with other orthogonal tests, such as cell-free DNA, which could provide an efficient route to diagnosis. Cancer treatment can be more effective when given earlier, and this low-cost strategy has the potential to improve patient prognosis.© 2023. The Author(s).